New drug duo takes on hard-to-treat blood cancer
NCT ID NCT07455851
First seen Mar 24, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This study tests a new drug, REGN17372, combined with another drug, linvoseltamab, in people whose multiple myeloma has returned or stopped responding to treatment. The goal is to find a safe dose and see if the combination shrinks tumors better than linvoseltamab alone. About 150 adults who have tried at least three prior treatments will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Illawarra Cancer care centre, Wollongong Hospital
RECRUITINGWollongong, New South Wales, 2500, Australia
-
Prince of Wales Hospital
RECRUITINGRandwick, New South Wales, 2031, Australia
Conditions
Explore the condition pages connected to this study.